Back to search

Article

Population pharmacokinetics and exposure-response analysis of sotrovimab in the early treatment of COVID-19

2022-11-27

Abstract excerpt

Sotrovimab is a recombinant human monoclonal antibody that has been shown to prevent progression to hospitalization or death from severe disease in non-hospitalized high-risk patients with mild-to-moderate COVID-19 following either intravenous (IV) or intramuscular (IM) administration. Population pharmacokinetic (popPK) and exposure-response (ER) analyses were performed to characterize sotrovimab PK and the relati...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
8f10692b-3249-5480-aace-f86eeebbf139
DOI
10.1101/2022.11.23.22282478
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Population pharmacokinetics and exposure-response analysis of sotrovimab in the early treatment of COVID-19DOI 10.1101/2022.11.23.22282478
Characteristics and outcomes of patients with COVID-19 at high-risk of disease progression receiving sotrovimab, oral antivirals or no treatment in EnglandSemantic proximity
Safety, Virology, Pharmacokinetics, and Clinical Experience of High-dose Intravenous Sotrovimab for the Treatment of Mild to Moderate COVID-19: An Open-label Clinical TrialSemantic proximity
Effectiveness of Sotrovimab and Molnupiravir in community settings in England across the Omicron BA.1 and BA.2 sublineages: emulated target trials using the OpenSAFELY platformSemantic proximity
Characteristics and Outcomes of COVID-19 Patients Presumed to be Treated with Sotrovimab in NHS Hospitals in EnglandSemantic proximity
Effectiveness of Sotrovimab in Preventing COVID-19-related Hospitalizations or Deaths Among U.S. VeteransSemantic proximity
Comparative effectiveness of sotrovimab and molnupiravir for prevention of severe COVID-19 outcomes in non-hospitalised patients: an observational cohort study using the OpenSAFELY platformSemantic proximity
Emulation of a target trial from observational data to compare effectiveness of Casirivimab/Imdevimab and Bamlanivimab/Etesevimab for early treatment of non-hospitalized patients with COVID-19Semantic proximity
A Quantitative Systems Pharmacology Model of the Pathophysiology and Treatment of COVID-19 Predicts Optimal Timing of Pharmacological InterventionsSemantic proximity
Computational Determination of Toxicity Risks Associated with a Selection of Approved Drugs having Demonstrated Activity Against COVID- 19Semantic proximity
Integrated PBPK-EO Modeling of Osimertinib: Predicting Pharmacokinetics, Intracranial EGFR Engagement, and Optimal Dosing Strategies in Clinical SettingsSemantic proximity
Pharmacometric assessment of the <i>in vivo</i> antiviral activity of ivermectin in early symptomatic COVID-19Semantic proximity
Pharmacokinetic /Pharmacodynamic Considerations of Alternate Dosing Strategies of Tocilizumab in COVID-19Semantic proximity
Select a neighboring publication to make it the new centre.